WHAT IS CLAIMED IS:

1. A composition comprising a purified polypeptide for use in treating or preventing Dengue Fever or infection by Dengue Virus (DENV) in a subject having or being at risk for having or developing Dengue Fever or infection by DENV, said polypeptide comprising the amino acid sequence Xaa-Pro-Pro-Asp-Cys-Ala-Trp-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr (SEQ ID NO:19), wherein Xaa is any amino acid.

2. The composition of claim 1, for use in causing clinical or histological improvement of a DENV infection in the subject.

3. The composition of claim 1, for use in causing an improvement in or a delay in the onset of one or more of the histological characteristics of a DENV infection in the subject.

4. The composition of claim 1, for use in decreasing the antibody dependent enhancement (ADE) of a DENV infection.

5. The composition of any one of claims 1 to 4, wherein said infection by DENV is Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS).

6. The composition of claim 1, for use in inhibiting binding of an anti-DENV heterologous IgG immune complex (IC) to an FcγR.

7. The composition of claim 1, for use in inhibiting formation of IC that contribute to immunopathogenesis of the ADE of DENV infections.

8. The composition of claim 1, for use in inhibiting binding of DENV virions to IgG IC.

9. The composition of claim 1, for use in inhibiting binding of a DENV protein to an IgG immune complex.

10. The composition of claim 9, wherein said DENV protein is NS1.

11. The composition of claim 1, for use in inhibiting binding of TNF-α to IgG IC.

12. The composition of claim 1, for use in inhibiting binding of a DENV-IgG IC to FcγI, FcγIIa H131 allele, FcγIIa R131 allele, FcγRIIb, FcγRIIc, FcγRIIIa, or FcγIIIb.

13. The composition of claim 1, for use in inhibiting binding of DENV-IgG IC to mC1q or sC1q.

14. The composition of claim 1, wherein said polypeptide comprises the amino acid sequence Ala-Pro-Pro-Asp-Cys-Ala-Trp-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr (SEQ ID NO:20).

CLAIMS

1. An invention not claimed in any divisional application.